Will you now recommend enfortumab and pembrolizumab for most patients with metastatic urothelial carcinoma, regardless of platinum eligibility, based on the EV 302 presentation at ESMO 2023?

Will you now recommend enfortumab + pembrolizumab for cis-eligible metastatic urothelial ca based on EV-302 data at ESMO 2023?

• Yes, will recommend for most patients (cisplatin eligible + cisplatin ineligible)
• No, awaiting published manuscript
• No, awaiting formal regulatory approval
• No, plan to continue using platinum doublet + avelumab (JAVELIN)
• No, will start using platinum doublet + nivolumab (CM-901)
• Other